ClinicalTrials.gg
RecruitingNCT06998134Updated Jul 23, 2026

Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults

An observational study in Muscle Weakness and Problems Moving Their Arms and Legs, sponsored by National Institutes of Health Clinical Center (CC). Recruiting at 1 site in United States. Open to participants aged 5 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by National Institutes of Health Clinical Center (CC) · Observational

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
23
Ages
5 Years to 25 Years
Sex
All
01

Study summary

People with cerebral palsy (CP), muscular dystrophy (MD), spina bifida, or spinal cord injury often have muscle weakness, and problems moving their arms and legs. The NIH designed a new brace device, called an exoskeleton, that is worn on the legs and helps people walk. This study is investigating new ways the exoskeleton can be used in multiple settings while performing different walking or movement tasks, which we call ubiquitous use. For example, we will ask you to walk on a treadmill at different speeds, walk up and down a ramp, or walk through an obstacle course. Optionally, the exoskeletons may also use functional electrical stimulation (FES), a system that sends electrical pulses to the muscle to help it move the limb.

Read the detailed description

STUDY DESCRIPTION:

The following exploratory observational study is designed to create a framework that permits rapid development, piloting, and acute evaluation of pediatric exoskeleton control paradigms for daily, ubiquitous use across multiple settings. Most existing evaluations of pediatric exoskeleton control modes are limited to a flat walking task.The novelty of this study design is the translation of control modes to different functional tasks and comparisons between fixed and adaptive parameters across the tasks. Across all participants, three main control modes will be tested: assist, resist, and interleaved (alternating assist and resist). Control parameters will either be fixed for all tasks conducted or may adapt based on the motions of a given activity. Following informed consent and assent, screening, and calibration of control parameters, an acclimation period to the exoskeleton and control modes will occur. Each control mode will be tested across ubiquitous activities of daily living and outcomes will be compared to baseline (without wearing the exoskeleton). Our central hypothesis is that existing control paradigms that have been previously validated in walking can be successfully translated to improve knee extension deficiency and/or knee extensor muscle activity in multiple different functional mobility tasks.

OBJECTIVES:

  • Primary Objectives: 1) To evaluate acute biomechanical and neuromuscular effects of pediatric exoskeleton control paradigms on knee extension deficiency across ubiquitous tasks and 2) Assess whether controller behavior and performance align with the intent of its prescribed design consistently across tasks.
  • Secondary objectives: 1) Measuring functional performance of tasks conducted with each control paradigm and 2) Characterizing muscle activation of knee extensors during each task.

ENDPOINTS:

Primary Endpoints:

  • To evaluate knee extension deficiency, we will use 1) Peak knee extension and 2) Range of knee angle excursion (difference between maximum extension and flexion). These endpoints will be measured and compared between each control strategy within each task during the assessment visit.
  • To characterize controller behavior and performance, we will use the root mean square error (RMSE) between the exoskeleton knee torque profile delivered in real-time and the ideal knee torque profile computed from the user s kinematics. This endpoint will be measured during each assessment visit.

Secondary Endpoints:

-To evaluate functional performance in:

  • self-selected speed treadmill walking, overground walking, stairs, and ramps, we will use gait speed, stride length, and number of gait cycles.
  • variable-speed treadmill walking, we will use cadence, stride length, and number of gait cycles.
  • Timed Up and Go and stairs, we will use the duration of the task.
  • the Standardized Walking Obstacle Course, we will use the time to traverse the environment.
  • the 2-Minute Walk Test, we will use the distance covered during the task.
  • the squat test, we will use the number of squats completed.

These endpoints will be measured and compared between each control strategy used within each task during the assessment visit.

To characterize muscle activation, we will use 1) peak knee extensor activation during the task and 2) area under the normalized EMG curve over the duration of the task. These endpoints will be measured and compared between each control strategy used within each task during the assessment visit.

02

Conditions studied

  • Muscle Weakness
  • Problems Moving Their Arms and Legs

Keywords

  • Cerebral Palsy (CP)
  • muscular dystrophy (MD)
  • Spina Bifida
  • incomplete spinal cord injury
03

In context

Muscle Weakness

477 studies on the registry are indexed under Muscle Weakness; 73 are open to participants now.

This study's planned enrollment of 23 is below the median of 68 across 108 observational studies indexed under Muscle Weakness.

Browse Muscle Weakness studies →

Lead sponsor

National Institutes of Health Clinical Center (CC) is the lead sponsor of 375 studies on the registry; 27 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 19 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient age 5-25 cerebral palsy (CP), muscular dystrophy (MD), spina bifida, or spinal cord injury often have muscle weakness, and problems moving their arms and legs

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Provision of signed and dated separate and assent forms for screening purposes. Upon inclusion in the protocol, provision of signed and dated informed consent and assent forms to begin participation in the study will be necessary.
  • Stated willingness to comply with all study procedures and availability for the duration of the study, or alternatively, ability to do so based on parent report and physician observation during history and physical examination.
  • Age 5 to 25 years old. Importantly, we included young adults (18-25 years old) because longterm outcomes for adults with cerebral palsy include loss of ambulatory ability. While studies of conventional gait training in this population have been conducted, use of exoskeletons in this population is very limited. Given the potential benefit of exoskeletons to reduce knee extension deficiency, it is important to determine whether novel controllers we develop are also tolerated and effective in this age group.
  • Either has a gait pathology arising from a diagnosis of CP, MD, SB, or iSCI or has no gait pathology.
  • Knee joint range of motion of at least 25 degrees in the sagittal plane (knee extension/flexion) assessed with the hip extended in a supine position. Hamstring contracture as assessed by the straight leg raising test does not limit ability to participate in the study.
  • Ankle joint range of motion of at least 15 degrees in the sagittal plane (dorsi-plantarflexion) with the foot in neutral alignment.
  • Able to walk at least 10 feet without stopping with or without a walking aid.

Exclusion criteria

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Any neurological, musculoskeletal, or cardiorespiratory injury, health condition, or diagnosis other than CP, MD, SB, or iSCI that would affect the ability to walk as directed with the robotic exoskeleton.
  • A history of uncontrolled seizures in the past year.
  • Pregnancy based on self-reporting. We excluded pregnancy due to confounding factors of pregnancy on gait.
  • Adult unable to consent for themselves at screening visit.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
23 participants (estimated)

Groups and cohorts

  • Cerebral Palsy (CP)

    Male and female age 5-25

    Device: Extension assist knee ankle foot orthosis (EA-KAFO)

  • Incomplete Spinal Cord Injury

    Male and female age 5-25

    Device: Extension assist knee ankle foot orthosis (EA-KAFO)

  • Muscular Dystrophy

    Male and female age 5-25

    Device: Extension assist knee ankle foot orthosis (EA-KAFO)

  • Spina Bifida

    Male and female age 5-25

    Device: Extension assist knee ankle foot orthosis (EA-KAFO)

Interventions

  • DeviceExtension assist knee ankle foot orthosis (EA-KAFO)

    A lower limb exoskeleton that has one actuated degree of freedom at the knee (flexion/extension) and a passive degree of freedom at the ankle (plantar/dorsiflexion).

06

What researchers measure

Primary outcomes

  1. Evaluate acute biomechanical and neuromuscular effects of pediatric exoskeleton control paradigms on knee extension deficiency across ubiquitous tasks.

    To evaluate knee extension deficiency, we will use:1) Peak knee extension and2) Range of knee angle excursion (difference between maximum extension and flexion).These endpoints will be measured and compared between each control strategy within each task during the assessment visit.

    Time frame: 4 months

Secondary outcomes

  1. Assess whether controller behavior and performance align with the intent of its prescribed design consistently across tasks.

    To ensure controllers are appropriately developed for ubiquitous use, it is vital to determine whether their intended behavior is consistent with design specifications across tasks.

    Time frame: 4 months

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • NIH Clinical Center Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Publications

  • Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology. 2007 Jan 30;68(5):326-37. doi: 10.1212/01.wnl.0000252807.38124.a3. PubMed 17261678 ↗
  • Emery AE. The muscular dystrophies. Lancet. 2002 Feb 23;359(9307):687-95. doi: 10.1016/S0140-6736(02)07815-7. PubMed 11879882 ↗
  • Mitchell LE, Adzick NS, Melchionne J, Pasquariello PS, Sutton LN, Whitehead AS. Spina bifida. Lancet. 2004 Nov 20-26;364(9448):1885-95. doi: 10.1016/S0140-6736(04)17445-X. PubMed 15555669 ↗
  • McDonald JW, Sadowsky C. Spinal-cord injury. Lancet. 2002 Feb 2;359(9304):417-25. doi: 10.1016/S0140-6736(02)07603-1. PubMed 11844532 ↗
  • Damiano DL, Abel MF. Relation of gait analysis to gross motor function in cerebral palsy. Dev Med Child Neurol. 1996 May;38(5):389-96. doi: 10.1111/j.1469-8749.1996.tb15097.x. PubMed 8698147 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Aug 2028, 25 months after the start.

Of 48 non-industry observational studies under Muscle Weakness, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 25 months is close to that.

Counting every sponsor, half of 50 studies reached it within 26 months; a quarter within 12 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
May 31, 2025
StartActual
Jun 23, 2026
Primary completionEst.
Aug 18, 2028
CompletionEst.
Aug 18, 2028
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06998134
Responsible party
Sponsor
First posted
May 31, 2025
Start date
Jun 23, 2026
Primary completion
Aug 18, 2028 (estimated)
Completion
Aug 18, 2028 (estimated)
Last update
Jul 23, 2026

Study contacts

Jesse H Matsubara
Contact
jesse.matsubara@nih.gov
(301) 451-7530
Thomas C Bulea, Ph.D.
Contact
buleatc@mail.nih.gov
(301) 451-7533
Thomas C Bulea, Ph.D.
principal investigator · National Institutes of Health Clinical Center (CC)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion